Cascadian Therapeutics Inc. (CASC)

10.02
Prev Close 10.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.18 / 10.21
Avg Volume 891.90K
Exchange
Shares Outstanding 50.55M
EPS -1.20
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc.

Cascadian Therapeutics Reaches Analyst Target Price

Cascadian Therapeutics Reaches Analyst Target Price

In recent trading, shares of Cascadian Therapeutics Inc have crossed above the average analyst 12-month target price of $8.50, changing hands for $10.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Cascadian Therapeutics, Inc. To Seattle Genetics, Inc. For $10.00 Per Share Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Cascadian Therapeutics, Inc. To Seattle Genetics, Inc. For $10.00 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Cascadian Therapeutics, Inc.

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc.

Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

Removes Requirement for Pediatric Clinical Studies to Support Tucatinib Market Authorization Application for Treatment of Metastatic Breast Cancer in Europe

Prolonged Progression-Free Survival Reinforces Tucatinib's Potential For Patients With Advanced HER2+ Metastatic Breast Cancer

Prolonged Progression-Free Survival Reinforces Tucatinib's Potential For Patients With Advanced HER2+ Metastatic Breast Cancer

Subgroup Analysis from Two Ongoing Combination Studies of Tucatinib Demonstrates Prolonged PFS Benefit Regardless of Presence of Brain Metastases or Patient Characteristics

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

Conference Call Scheduled for Today at 4:30 p.m. ET

Cascadian Therapeutics Stock Sees Short Interest Decrease By 15.2%

Cascadian Therapeutics Stock Sees Short Interest Decrease By 15.2%

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 348,106 share decrease in total short interest for Cascadian Therapeutics Inc , to 1,937,349, a decrease of 15.23% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cascadian Therapeutics Announces Positive Regulatory Update For Tucatinib In Europe

Cascadian Therapeutics Announces Positive Regulatory Update For Tucatinib In Europe

EMA Confirms Single HER2CLIMB Trial, If Positive, Could Support Approval

Interesting CASC Put And Call Options For February 2018

Investors in Cascadian Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.